Exploring the illegal drug issue in international context, this book looks at why harmonization has not already taken place at the European level. It considers the desirability and viability of harmonization, examines the conflict between repressive and liberal drug policies and applies a multi-level governance lens to the issue.
Martin Elvins' book is the first to trace the evolution of anti-drugs policies at European Union level from the late 1960s to the present. Phases of drug policy development, key policy actors and institutions are described with particular reference to the influence of transnational networks of expertise. Policy development is placed in the context of both European integration and a broad harmonization of international policies against drug trafficking. Concerns are also raised about secretive and anti-democratic features on intergovernmental EU decision-making.
While there may be consensus on the broader issues of the core objectives of the health care system, expectations differ between EU countries, and European national policy-makers. This book seeks firstly to assess the impact of the enlargement process and then to analyse the challenges that lie ahead in the field of health and health policy.
Medical devices that are deemed to have a moderate risk to patients generally cannot go on the market until they are cleared through the FDA 510(k) process. In recent years, individuals and organizations have expressed concern that the 510(k) process is neither making safe and effective devices available to patients nor promoting innovation in the medical-device industry. Several high-profile mass-media reports and consumer-protection groups have profiled recognized or potential problems with medical devices cleared through the 510(k) clearance process. The medical-device industry and some patients have asserted that the process has become too burdensome and is delaying or stalling the entry of important new medical devices to the market. At the request of the FDA, the Institute of Medicine (IOM) examined the 510(k) process. Medical Devices and the Public's Health examines the current 510(k) clearance process and whether it optimally protects patients and promotes innovation in support of public health. It also identifies legislative, regulatory, or administrative changes that will achieve the goals of the 510(k) clearance process. Medical Devices and the Public's Health recommends that the U.S. Food and Drug Administration gather the information needed to develop a new regulatory framework to replace the 35-year-old 510(k) clearance process for medical devices. According to the report, the FDA's finite resources are best invested in developing an integrated premarket and postmarket regulatory framework.
Analysing arguably one of the most controversial areas in public policy, this pioneering Research Handbook brings together contributions from expert researchers to provide a global overview of the shifting dynamics of drug policy. Emphasising connections between the domestic and the international, contributors illustrate the intersections between drug policy, human rights obligations and the 2030 Sustainable Development Agenda, offering an insightful analysis of the regional dynamics of drug control and the contemporary and emerging problems it is facing.
People have always travelled within Europe for work and leisure, although never before with the current intensity. Now, however, they are travelling for many other reasons, including the quest for key services such as health care. Whatever the reason for travelling, one question they ask is "If I fall ill, will the health care I receive be of a high standard?" This book examines, for the first time, the systems that have been put in place in all of the European Union's 27 Member States. The picture it paints is mixed. Some have well developed systems, setting standards based on the best available evidence, monitoring the care provided, and taking action where it falls short. Others need to overcome significant obstacles.
The drug control regime established by the international community has not succeeded in curbing either the demand for, or the offer of, narcotics. But, despite a series of developments in the Americas – including the legalisation of cannabis in Uruguay and in several states in the United States of America – there is still little support in Europe for repealing drug-prohibition laws. Nevertheless, a gradual policy convergence reveals the emergence of a European model favouring public-health strategies over a strictly penal approach to combatting drugs, while growing transnational support for legalisation indicates the persistence of an alternative paradigm for drug policy. This book examines the various influences on drug policies in Europe, as grassroots movements, NGO networks, private foundations and academic research centres increasingly confront the prevailing discourses of drug prohibition. Pursuing an interdisciplinary approach and bringing together legal scholars, social scientists and practitioners, it provides a comprehensive and critical assessment of drug policy reform in Europe.
This book examines the topical issue of global drug policy and outlines five steps that could be taken to improve its effectiveness. A public criminology approach is applied to explore not only what could be done, but also why it matters and how it could be achieved. It argues that more effective global drug policies require an acknowledgement of the failure of a war on drugs approach and the harms it has caused. Instead, strategies that reduce drug related harm should be prioritised. An innovative and diverse range of approaches should be developed that are underpinned by evaluation and dissemination of results. Finally, the horizons of the drug policy debate should be broadened. In line with the central aims of public criminology, this book provides an accessible contribution to global drug policy debates that links theory and practice and which will have appeal to a wide range of audiences.
The 2016 UNGASS on drug policy resulted in an Outcome Document detailing profound differences of opinion and practice between different states polarising public health and human rights themes. This book examines the different positions, the underlying problems, and the options open for the next international gathering on drugs.
This new book brings together some of the leading criminologists across Europe, to showcase the best of European criminology. This Handbook aims to reflect the range and depth of current work in Europe, and to counterbalance the impact of the – sometimes insular and ethnocentric – Anglo-American criminological tradition. The end-product is a collection of twenty-eight chapters illustrating a truly comparative and interdisciplinary European criminology. The editors have assembled a cast of leading voices to reflect on differences and commonalities, elaborate on theoretically grounded comparisons and reflect on emerging themes in criminology in Europe. After the editors’ introduction, the book is organised in three parts: five chapters offering historical, theoretical and policy oriented overviews of European issues in crime and crime control; seven chapters looking at different dimensions of crime in Europe, includingcrime trends, state crime, gender and crime and urban safety; fifteen chapters examining the variety of institutional responses, exploring issues such as policing, juvenile justice, punishment, green crime and the role of the victim. This book gives some indication of the richness and scope of the emerging comparative European criminology and will be required reading for anyone who wants to understand trends in crime and its control across Europe. It will also be a valuable teaching resource, especially at postgraduate level, as well as an important reference point for researchers and scholars of criminology across Europe.